COMPANY PROFILE

Deargen

AI-powered drug design biotech company advancing treatments for rare and intractable diseases through genome data analysis and molecule optimization

Daejeon, South KoreaFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Deargen

Deargen Inc. is a biotechnology company that leverages advanced Artificial Intelligence (AI) to revolutionize the development of new drugs, particularly for rare and intractable diseases. The company operates in the pharmaceutical and healthcare markets, focusing on integrating AI with drug discovery processes to enhance efficiency and precision. Deargen's AI platform, Dr.UG, utilizes deep learning technology to analyze genome data, predict biomarkers, and select and optimize molecules for drug development. This approach allows Deargen to identify new disease targets and design small molecules for precision medicine.

Deargen serves pharmaceutical companies, research institutions, and healthcare providers who are looking for innovative solutions to accelerate drug discovery and development. The company's business model is based on partnerships and collaborations, both corporate and scientific, to co-develop new treatments and bring them to market. Revenue is generated through these partnerships, licensing agreements, and potentially through the commercialization of successful drug candidates.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Daejeon, South Korea
Employees: 11
Open positions: None listed
Dealroom signal: 69.0/100
Industry: Health
Sub-industry: BioTechnology, Health Platform
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Precision Medicine, Spinout, Tech for Biotech and Pharma, Techbio, NIF defense security and resilience
Technology: Artificial Intelligence, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Feb 2022	$17M	$68M	TS Investment · Korea Development Bank · Hana Ventures	—
SEEDEquity / VC	Nov 2020	$2.5M	$10M	Hana Ventures · TS Investment · Amyloid Solution	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Deargen website traffic

Latest recorded traffic for Deargen is 2.5K monthly website visits, up 19% over the last three months. Deargen's team declined 8.3% over the past year.

Latest monthly visits2.5K 3-month web change+19% 1-year team growth-8.3%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ILiLoFAI and photonics platform for personalized drug discovery.	London, United Kingdom	Operational	40	$13M	$22M
VDValence DiscoveryAI-first design of novel chemistry against previously intractable biology	Montreal, Canada	Acquired
KUKuanoUsing machine learning and quantum physics to simulate, filter, and discover new molecules	Cambridge, United Kingdom	Operational
OWOwkinCollaborative research platform and unique AI drug development solutions that make precision medicine a reality	Paris, France	Operational
OMOmniscopeAI-powered immune databank for diagnostics and therapeutics	Barcelona, Spain	Operational
MTMETiS TherapeuticsAI-driven platform for drug discovery and delivery	Cambridge, United States	Operational
SBSibylla BiotechFacing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs	Bresso, Italy	Operational
AQAqemiaUsing quantum-physics with AI to speed up the discovery of novel drug molecules	Paris, France	Operational